NCT07023068

⁶⁸Ga-DPA in the Lung Cancer Diagnosis

Clinical Application of PD-L1 Targeted Imaging Agent ⁶⁸Ga-DPA in the Diagnosis of Lung Cancer

• Status: Enrolling By Invitation
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

In previous studies, we synthesized a PD-L1-targeted molecular probe, ⁶⁸Ga-DPA, and developed a ⁶⁸Ga-DPA injection for clinical research. Preliminary studies demonstrated its favorable safety profile and excellent imaging performance. Leveraging the established strengths of the Department of Nuclear Medicine at Peking Union Medical College Hospital, we now plan to conduct an exploratory PET/CT imaging study in lung cancer patients. This study aims to provide an in vivo, non-invasive, and visualizable technique for detecting PD-L1 expression levels and spatial distribution in tumors. It will further validate the clinical utility of this technology, offering critical diagnostic insights for initial assessment and treatment efficacy evaluation in PD-L1-positive tumor patients undergoing PD-L1-targeted therapies.

Conditions

• Lung Cancers

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	68Ga-DPA PET/CT	Use 68Ga-DPA PET/CT in the diagnosis of lung cancer

Timeline

• Start date: 2024-09-28
• Primary completion: 2026-09-28
• Completion: 2027-09-28
• First posted: 2025-06-15
• Last updated: 2025-06-15

Locations

1 site across 1 country: China